See more : HY Electronic (Cayman) Limited (6573.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Chembio Diagnostics, Inc. (CEMI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chembio Diagnostics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Laybuy Group Holdings Limited (LBY.AX) Income Statement Analysis – Financial Results
- Kerry Group plc (KRYAF) Income Statement Analysis – Financial Results
- Sabuy Technology Public Company Limited (SABUY.BK) Income Statement Analysis – Financial Results
- Eargo, Inc. (EAR) Income Statement Analysis – Financial Results
- O.A.T., Inc. (OATN) Income Statement Analysis – Financial Results
Chembio Diagnostics, Inc. (CEMI)
About Chembio Diagnostics, Inc.
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as sells its products directly through distributors to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 48.34M | 36.93M | 30.45M | 34.46M | 33.41M | 24.02M | 17.87M | 24.26M | 27.65M | 29.55M | 25.61M | 19.39M | 16.70M | 13.83M | 11.05M | 9.23M | 6.50M | 3.94M | 3.31M | 0.00 | 0.00 | 0.00 | 1.00 |
| Cost of Revenue | 38.58M | 34.50M | 23.87M | 22.39M | 21.43M | 12.92M | 9.42M | 13.77M | 16.83M | 17.25M | 14.82M | 10.00M | 8.60M | 7.97M | 7.20M | 5.37M | 4.49M | 2.61M | 2.49M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 9.76M | 2.43M | 6.58M | 12.07M | 11.98M | 11.09M | 8.45M | 10.49M | 10.81M | 12.30M | 10.79M | 9.39M | 8.10M | 5.86M | 3.85M | 3.86M | 2.02M | 1.33M | 820.34K | 0.00 | 0.00 | 0.00 | 1.00 |
| Gross Profit Ratio | 20.19% | 6.58% | 21.60% | 35.02% | 35.86% | 46.20% | 47.30% | 43.23% | 39.12% | 41.63% | 42.13% | 48.43% | 48.49% | 42.36% | 34.86% | 41.84% | 31.01% | 33.80% | 24.81% | 0.00% | 0.00% | 0.00% | 100.00% |
| Research & Development | 7.07M | 12.49M | 9.51M | 8.54M | 8.53M | 8.56M | 8.43M | 6.38M | 4.83M | 5.83M | 4.49M | 4.88M | 2.59M | 2.88M | 2.61M | 1.91M | 1.40M | 1.36M | 1.43M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.15M | 5.73M | 4.48M | 3.55M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44.28K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.51M | 1.78M | 1.01M | 1.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 765.00 | 0.00 | 0.00 |
| SG&A | 24.28M | 24.84M | 21.04M | 16.14M | 11.10M | 9.02M | 7.60M | 7.66M | 7.50M | 5.49M | 4.85M | 3.42M | 2.94M | 2.66M | 3.32M | 4.83M | 5.20M | 3.24M | 2.49M | 3.11K | 45.05K | 6.73K | 128.83K |
| Other Expenses | -1.18M | -10.89M | -2.02M | 0.00 | 0.00 | 0.00 | 0.00 | -4.81K | -5.71K | 7.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 30.16M | 26.44M | 28.53M | 24.68M | 19.63M | 17.58M | 16.02M | 14.04M | 12.36M | 11.30M | 9.34M | 8.30M | 5.53M | 5.54M | 5.92M | 6.74M | 6.61M | 4.63M | 3.92M | 7.12K | 47.02K | 6.73K | 130.77K |
| Cost & Expenses | 68.74M | 60.93M | 52.40M | 47.07M | 41.05M | 30.50M | 25.44M | 27.81M | 29.20M | 28.54M | 24.16M | 18.30M | 14.13M | 13.52M | 13.12M | 12.11M | 11.10M | 7.24M | 6.41M | 7.12K | 47.02K | 6.73K | 130.77K |
| Interest Income | 0.00 | 0.00 | 0.00 | -846.83K | 49.50K | 25.43K | 25.55K | 2.41K | 5.84K | 5.78K | 7.91K | 6.30K | 4.15K | 9.03K | 34.40K | 145.29K | 29.53K | 39.80K | 8.13K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 382.00K | 2.91M | 2.84M | -846.83M | 0.00 | 2.95K | 0.00 | 836.00 | 0.00 | 335.00 | 9.50K | 18.62K | 14.73K | 10.60K | 8.32K | 16.88K | 386.90K | 15.68K | 190.56K | 0.00 | 635.00 | 0.00 | 14.00 |
| Depreciation & Amortization | 5.79M | 2.93M | 2.70M | 721.47K | 337.65K | 1.28M | 1.14M | 1.37M | 739.30K | 607.82K | 523.28K | 437.83K | 283.74K | 362.34K | 345.39K | 283.36K | 209.54K | 98.51K | 109.97K | 4.01K | 367.00 | 63.41K | 176.00 |
| EBITDA | -14.61M | -21.07M | -19.25M | -11.89M | -7.31M | -5.18M | -6.41M | -2.18M | -810.82K | 1.63M | 1.45M | 1.53M | 2.86M | 688.70K | -1.69M | -2.71M | -4.33M | -3.20M | -3.18M | -11.62K | -46.65K | 56.67K | -132.51K |
| EBITDA Ratio | -30.23% | -57.07% | -63.23% | -34.49% | -21.87% | -21.57% | -35.86% | -9.00% | -2.93% | 5.50% | 5.67% | 7.90% | 17.13% | 4.98% | -15.30% | -29.40% | -66.58% | -81.19% | -96.20% | 0.00% | 0.00% | 0.00% | -13,251,300.00% |
| Operating Income | -20.40M | -24.01M | -21.95M | -12.61M | -7.65M | -6.48M | -7.57M | -3.55M | -1.55M | 1.00M | 1.45M | 1.09M | 2.57M | 317.33K | -2.07M | -2.88M | -4.60M | -3.30M | -3.10M | -7.12K | -47.02K | -6.73K | -130.77K |
| Operating Income Ratio | -42.21% | -65.01% | -72.08% | -36.58% | -22.88% | -26.99% | -42.37% | -14.65% | -5.61% | 3.40% | 5.67% | 5.61% | 15.41% | 2.29% | -18.74% | -31.16% | -70.68% | -83.69% | -93.87% | 0.00% | 0.00% | 0.00% | -13,076,900.00% |
| Total Other Income/Expenses | 381.80K | -9.96M | -2.84M | -846.83K | 49.50K | 22.49K | 25.55K | -3.24K | 132.00 | 12.94K | -1.58K | -12.33K | -14.50K | -8.27K | 121.90K | 249.27K | -398.83K | 45.99K | 186.90K | 8.51K | 0.00 | -63.41K | 1.92K |
| Income Before Tax | -23.26M | -33.97M | -25.98M | -14.18M | -7.93M | -6.46M | -7.55M | -3.56M | -1.55M | 1.02M | 1.45M | 1.08M | 2.56M | 309.06K | -1.95M | -2.63M | -5.00M | -3.25M | -2.92M | 1.39K | 0.00 | -70.14K | -128.85K |
| Income Before Tax Ratio | -48.11% | -91.98% | -85.31% | -41.13% | -23.75% | -26.90% | -42.23% | -14.67% | -5.61% | 3.44% | 5.66% | 5.55% | 15.32% | 2.23% | -17.64% | -28.46% | -76.82% | -82.52% | -88.22% | 0.00% | 0.00% | 0.00% | -12,884,900.00% |
| Income Tax Expense | 34.41K | -62.05K | -456.79K | -500.29K | -67.52K | -88.31K | 5.80M | -1.16M | -412.92K | 486.95K | 509.24K | -5.13M | 45.82K | 10.60K | 8.32K | -249.27K | 398.83K | -24.12K | -4.47K | -8.51K | 635.00 | 2.67K | -1.91K |
| Net Income | -23.29M | -33.90M | -25.52M | -13.68M | -7.87M | -6.37M | -13.35M | -2.40M | -1.14M | 530.82K | 941.28K | 6.21M | 2.51M | 309.06K | -1.95M | -2.63M | -5.00M | -3.25M | -3.10M | 1.39K | -47.65K | -72.82K | -128.86K |
| Net Income Ratio | -48.18% | -91.81% | -83.81% | -39.68% | -23.54% | -26.53% | -74.69% | -9.88% | -4.11% | 1.80% | 3.68% | 32.02% | 15.05% | 2.23% | -17.64% | -28.46% | -76.82% | -82.52% | -93.74% | 0.00% | 0.00% | 0.00% | -12,886,400.00% |
| EPS | -0.96 | -1.40 | -1.34 | -0.81 | -0.54 | -0.52 | -1.26 | -0.25 | -0.12 | 0.06 | 0.12 | 0.79 | 0.32 | 0.04 | -0.25 | -1.44 | -3.88 | -3.38 | -4.15 | 0.18 | -5.95 | -35.43 | -115.16 |
| EPS Diluted | -0.96 | -1.40 | -1.34 | -0.81 | -0.54 | -0.52 | -1.26 | -0.25 | -0.12 | 0.06 | 0.11 | 0.73 | 0.32 | 0.03 | -0.25 | -1.44 | -3.88 | -3.38 | -4.15 | 0.18 | -5.95 | -35.43 | -115.16 |
| Weighted Avg Shares Out | 24.30M | 24.30M | 19.09M | 16.95M | 14.43M | 12.30M | 10.62M | 9.63M | 9.53M | 8.99M | 7.99M | 7.87M | 7.76M | 7.74M | 7.66M | 1.83M | 1.29M | 963.22K | 745.85K | 132.89K | 136.19K | 34.94K | 19.02K |
| Weighted Avg Shares Out (Dil) | 24.30M | 24.30M | 19.09M | 16.95M | 14.43M | 12.30M | 10.62M | 9.63M | 9.53M | 9.52M | 8.61M | 8.56M | 8.87M | 9.38M | 7.66M | 1.83M | 1.29M | 963.22K | 745.85K | 132.89K | 136.19K | 34.94K | 19.02K |
CEMI Stock: One Huge Reason Chembio Is Rocketing Higher Today
CEMI stock is soaring today after the company announced the commercial launch of a rapid Covid-19 test that was met with significant optimism. The post CEMI Stock: One Huge Reason Chembio Is Rocketing Higher Today appeared first on InvestorPlace.
Chembio Diagnostics stock rockets on record volume after commercial launch of rapid COVID-19 test
Shares of Chembio Diagnostics Inc. skyrocketed 63.8% on record volume in afternoon trading Monday, to pace all gainers listed on major U.S. exchanges, in the wake of the point-of-care diagnostics company's announcement of the commercial launch of its rapid COVID-19/flu...
Why NNOX Stock And CEMI Stock Are Skyrocketing Today
Chembio Diagnostics Inc (NASDAQ: CEMI) shares are trading higher by 41% in Monday's pre-market session after the company announced the commercial launch of a test to differentiate between COVID-19 and the Flu. Chembio develops, manufactures, and commercializes point-of-care (POC) diagnostic...
Chembio Diagnostics Stock Price Increased Over 60% Pre-Market: Why It Happened
The stock price of Chembio Diagnostics (NASDAQ: CEMI) increased by over 60% pre-market. This is why it happened.
Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu
In-licensed Rapid Point-of-Care Test Available for Use in Detecting COVID-19 Antigens, Flu A and Flu B from a Single Patient Sample in 15 Minutes In-licensed Rapid Point-of-Care Test Available for Use in Detecting COVID-19 Antigens, Flu A and Flu B...
Chembio Diagnostics' (CEMI) CEO Rick Eberly on Q4 2020 Results - Earnings Call Transcript
Chembio Diagnostics' (CEMI) CEO Rick Eberly on Q4 2020 Results - Earnings Call Transcript
Chembio Diagnostics to Report Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021
HAUPPAUGE, N.Y., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the fourth quarter and full year 2020 after the...
Chembio Diagnostics Appoints David Acheson, M.D. to its Board of Directors
HAUPPAUGE, N.Y., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the appointment of David Acheson, M.D. to the Company's Board of Directors.
Chembio Diagnostics Awarded $12.7 Million by BARDA for Development of Rapid DPP Respiratory Antigen Panel and 510(k) Submission of the Rapid DPP SARS-CoV-2 Antigen Test System
HAUPPAUGE, N.Y., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI) a leading point-of-care diagnostic company focused on infectious diseases, today announced it has been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), which is...
Is Chembio Diagnostics Inc (CEMI) A Good Stock To Buy?
In this article we will take a look at whether hedge funds think Chembio Diagnostics Inc (NASDAQ:CEMI) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend...
Source: https://incomestatements.info
Category: Stock Reports